In sum, our current findings identify DNMT1-KIT-PD-L1 cascade as a unique resistance mechanism to cisplatin and provide insight into future therapeutic strategies for the treatment of cisplatin-refractory SCLC patients. This evidence concerns the gene DNMT1 and small cell lung carcinoma.